830 / 1835
Conclusions
•
Anti-PD1 mAb are likely to play an important role in management of
relapsed and refractory HL
•
Role of anti-PD1 in other lymphoma much less well defined and requires
further study most likely in combinations with RT other immune
checkpoint inhibitors and targeted therapies
•
Timing dose and scheduling of RT with immunoregulatory agents requires
further investigation
•
Many new immune checkpoint inhibitors being investigated (Tim-3, Lag-3)
•
Biomarkers of response and toxicity required